{"subsection_name": null, "pub_date": "2011-10-25T14:42:54Z", "byline": {"original": "By DUFF WILSON", "person": [{"lastname": "WILSON", "organization": "", "rank": 1, "role": "reported", "firstname": "Duff"}]}, "abstract": "The arrangements, the agency says, result in slowing the marketing of less expensive drugs.", "word_count": 583, "print_page": null, "news_desk": null, "snippet": "The arrangements, the agency says, result in slowing the marketing of less expensive drugs.", "multimedia": [], "source": "The New York Times", "blog": [], "keywords": [{"name": "subject", "value": "Suits and Litigation", "rank": "4"}, {"name": "subject", "value": "Generic Brands and Products", "rank": "3"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": "2"}, {"name": "organizations", "value": "Federal Trade Commission", "rank": "5"}, {"name": "type_of_material", "value": "News", "rank": "1"}], "type_of_material": "Blog", "lead_paragraph": "Updated: 5:30 p.m. Drug companies negotiated 28 potential \"pay-for-delay\" deals that slowed the marketing of cheaper generic drugs in the fiscal year ending Sept. 30, the Federal Trade Commission said Tuesday in a staff report.", "web_url": "http://prescriptions.blogs.nytimes.com/2011/10/25/f-t-c-28-pay-for-delay-generic-drug-deals/", "section_name": "Health", "headline": {"main": "F.T.C.: 28 'Pay-for-Delay' Generic Drug Deals", "kicker": "Prescriptions"}, "slideshow_credits": null, "_id": "4fd3a1628eb7c8105d8e8002", "document_type": "blogpost"}